Ovarian Tumor Targeting of Docetaxel-Loaded Liposomes Mediated by Luteinizing Hormone-Releasing Hormone Analogues

Abstract

Recent studies indicate that luteinizing hormone-releasing hormone (LHRH) analogues (LHRHa), like LHRH, are able to specifically bind to LHRH receptors which are highly expressed on the extracellular membrane of ovarian tumor cells. As a targeting moiety, LHRHa can mediate the ovarian tumor targeting of docetaxel-loaded liposomes. In our study, synthesized negatively charged cholesterol succinimide (CHS) was employed for the preparation of negatively charged docetaxel-loaded liposomes, with which the positively charged LHRHa is linked via electrostatic absorption. An HPLC-based assay for determination of docetaxel (CAS 114977-28-5, Doc) in vivo and the model of ovarian cancer xenograft were established to investigat the biodistribution of docetaxel, docetaxel liposomes (Doc-Lipo), and LHRHa mediated docetaxel-loaded liposomes (LHRHa-Doc-Lipo) in nude mice. Sixty minutes after administration of LHRHa-Doc-Lipo, the concentration of docetaxel in the ovarian tumor was 2.86 times that of Doc-Lipo and 9.02 times that of Doc in the nude mice bearing ovarian tumor. LHRHa-Doc-Lipo decreased the concentration of docetaxel in the liver and spleen by 57% and 34%, respectively, as compared with Doc-Lipo. Therefore, LHRHa-Doc-Lipo exhibits potentiality as an active targeting drug delivery system for chemotherapy of ovarian tumor.

Key words

CAS 114977-28-5 - Docetaxel, in vivo distribution, liposomes, nude mice - Liposomes, docetaxel-loaded - Luteinizing hormone-releasing hormone analogues - Ovarian tumor targeting

• References

• 1 Dharap SS, Qiu B, Williams GC, Sinko P, Stein S, Minko T. Molecular targeting of drug delivery systems to ovarian cancer. J Controlled Release. 2003; 91: 61-73
• 2 Dimitra CB, Eugenia P, Vassiliki M, George NP, Evy MZ, Paul A et al. Conformational analysis of the nonapeptide leuprorelin using NMR and molecular modeling. J Lett Pept Sci. 2002; 8: 77-87
• 3 Peter VCG, Oswald S, Klaus DS, Günter E. Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: Frequency, auto-regulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol. 2002; 186: 171-179
• 4 Guan R, Cui Y. Application of LHRH analogues in treatment of ovarian cancer. J Woman Child Health Res. 2003; 14 (6) 413-416 (in Chinese)
• 5 Miyazaki M, Schally AV, Nagy A. Targeted cytotoxic analog of luteinizing hormone2releasing hormone AN-207 inhibits growth of OV21063 human epithelial ovarian cancers in nudemice. Am J Obstet Gynecol. 1999; 80: 1095-1103
• 6 Markman M, Kennedy A, Webster K. Combination chemotherapy with carbop latin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum. J Clin Oncol. 2001; 19: 1901-1905
• 7 Maria LI, Paola B, Silvia A, Barbara S, Franco D, Luigi C. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Controlled Release. 2003; 91: 417-429
• 8 da Cruz MT, Simoes S, Pedroso de Lima MC. Improving lipoplex-mediated gene transfer into C6 glioma cells and primary neurons. J Exp Neurol. 2004; 187: 65-75
• 9 Wu CC, Li LY, Zhang D, Song H. Research on synthesis of monocholesterylsuccinate. J Tianjin Polytechnic University. 2005; 6 (4) 27-33 (in Chinese)
• 10 Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Controlled Release. 2007; 120: 18-26
• 11 Tros de Ilarduya C, Arangoa MA, Moreno-Aliaga MJ, Duzgunes N. Enhanced gene delivery in vitro and in vivo by improved transferrin-lipoplexes. J Biochim Biophys Acta. 2002; 1561: 209-221